利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

44 条记录 (耗时 0.041 秒)

    Mutated recombinant collagens
    16.
    发明授权
    Mutated recombinant collagens 失效
    突变的重组胶原

    公开(公告)号：US06653450B1

    公开(公告)日：2003-11-25

    申请号：US08278774

    申请日：1994-07-22

    申请人： Richard A. Berg ,  Paul David Toman ,  Donald G. Wallace

    发明人： Richard A. Berg ,  Paul David Toman ,  Donald G. Wallace

    IPC分类号： C07K1400

    CPC分类号： A23C9/20 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/05 ,  A01K2227/10 ,  A01K2227/105 ,  A01K2267/01 ,  A23C2230/05 ,  A23J1/20 ,  A23J3/06 ,  A61K38/00 ,  C07K14/78 ,  C12N15/8509

    摘要： The invention provides recombinant procollagen chains having a natural collagen chain separated from one or two propeptides by one or two non-natural site-specific proteolytic agent (e.g., protease) recognition sites. A wide variety of propeptides and site-specific proteolytic agent recognition sites may be used: the selection of particular site-specific proteolytic agent/recognition site pairs is based on the conformation of the resulting procollagen, the availability of the site-specific proteolytic agent, the compatibility of the proteolysis with production of mature collagen, among other factors. Recombinant collagens chains are produced by contacting the subject recombinant procollagen chains with the appropriate site-specific proteolytic agents. Nucleic acids encoding the subject procollagen chains operably linked to transcription regulatory elements are used in vectors and cells for the production of recombinant collagen. Such collagen is used in tissue and cell cultureware and therapeutically, such as in biodegradable surgical materials and for tissue augmentation.

    摘要翻译： 本发明提供具有通过一个或两个非天然位点特异性蛋白水解剂（例如蛋白酶）识别位点从一个或两个前肽分离的天然胶原链的重组前胶原链。 可以使用各种前肽和位点特异性蛋白水解剂识别位点：特定位点特异性蛋白水解剂/识别位点对的选择基于所得原胶原的构象，位点特异性蛋白水解剂的可用性， 蛋白水解与成熟胶原蛋白的相容性等因素。 通过使本发明的重组前胶原链与适当的位点特异性蛋白水解剂接触来产生重组胶原链。 编码与转录调控元件可操作地连接的对象原胶原链的核酸用于生产重组胶原的载体和细胞中。 这种胶原蛋白被用于组织和细胞培养物以及治疗上，例如可生物降解的手术材料和用于组织增加。

    Compositions containing thrombin and microfibrillar collagen and methods for preparation and use thereof
    17.
    发明授权
    Compositions containing thrombin and microfibrillar collagen and methods for preparation and use thereof 有权
    含有凝血酶和微原纤维胶原的组合物及其制备和使用方法

    公开(公告)号：US06280727B1

    公开(公告)日：2001-08-28

    申请号：US09436903

    申请日：1999-11-09

    申请人： Jeffrey J. Prior ,  Donald G. Wallace ,  David H. Sierra ,  Frank A. DeLustro

    发明人： Jeffrey J. Prior ,  Donald G. Wallace ,  David H. Sierra ,  Frank A. DeLustro

    IPC分类号： A61K3800

    CPC分类号： A61L24/106 ,  A61L24/043 ,  A61L24/102 ,  A61L2400/04 ,  C08L89/06

    摘要： The present invention relates to thrombin-containing hemostatic compositions, their preparation and use. In particular, it relates to hemostatic compositions comprising stabilized thrombin and microfibrillar collagen in an aqueous medium. In a preferred embodiment of the present invention, the compositions are used in a kit comprising two different components, one of which is autologous patient's plasma as the source of fibrinogen, and the other of which is the thrombin-containing composition which also contains microfibrillar collagen.

    摘要翻译： 本发明涉及含凝血酶的止血组合物，其制备和用途。 具体地说，本发明涉及在水性介质中包含稳定的凝血酶和微原纤维胶原的止血组合物。 在本发明的优选实施方案中，组合物用于包含两种不同组分的试剂盒中，其中一种是自体患者的血浆作为纤维蛋白原的来源，另一种是含有含有微​​原纤维胶原蛋白的凝血酶组合物 。

    Injectable ceramic compositions and methods for their preparation and use
    18.
    发明授权
    Injectable ceramic compositions and methods for their preparation and use 失效
    可注射陶瓷组合物及其制备和使用方法

    公开(公告)号：US5352715A

    公开(公告)日：1994-10-04

    申请号：US101333

    申请日：1993-08-02

    申请人： Donald G. Wallace ,  Hugh McMullin ,  George Chu

    发明人： Donald G. Wallace ,  Hugh McMullin ,  George Chu

    IPC分类号： A61K47/02 ,  A61F2/00 ,  A61L27/00 ,  A61L27/10 ,  A61L27/12 ,  A61L27/24 ,  A61L27/46 ,  C08K3/32 ,  A61M31/00

    CPC分类号： A61L27/24 ,  A61L27/10 ,  A61L27/12 ,  A61L27/46 ,  C08K3/32 ,  A61F2310/00293

    摘要： Injectable implant compositions comprise a biocompatible ceramic matrix present in a fluid carrier, where the ceramic matrix comprises particles having a size distribution in the range from 50 .mu.m to 250 .mu.m. Optionally, the compositions may further comprise collagen, where the relative amounts of collagen and ceramic matrix at least partly determine the physical properties of implants formed by injecting the compositions. The fluid carrier is an aqueous buffered medium, typically including an organic polymer base material when there is no collagen present in the composition. The compositions are particularly suitable for repair and augmentation of soft and hard tissues by injection.

    摘要翻译： 可注射植入物组合物包含存在于流体载体中的生物相容性陶瓷基质，其中陶瓷基质包含尺寸分布在50μm至250μm范围内的颗粒。 任选地，组合物还可以包含胶原蛋白，其中胶原和陶瓷基质的相对量至少部分地决定通过注射组合物形成的植入物的物理性质。 流体载体是含水缓冲介质，当组合物中不存在胶原时，通常包括有机聚合物基料。 组合物特别适用于通过注射来修复和增加软组织和硬组织。